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Abstract
Background: Rhabdomyolysis is a clinical syndrome that comprises destruction of skeletal muscle with outflow of
intracellular muscle content into the bloodstream. There is a great heterogeneity in the literature regarding definition,
epidemiology, and treatment. The aim of this systematic literature review was to summarize the current state of
knowledge regarding the epidemiologic data, definition, and management of rhabdomyolysis.
Methods: A systematic search was conducted using the keywords “rhabdomyolysis” and “crush syndrome”
covering all articles from January 2006 to December 2015 in three databases (MEDLINE, SCOPUS, and
ScienceDirect). The search was divided into two steps: first, all articles that included data regarding definition,
pathophysiology, and diagnosis were identified, excluding only case reports; then articles of original research
with humans that reported epidemiological data (e.g., risk factors, common etiologies, and mortality) or
treatment of rhabdomyolysis were identified. Information was summarized and organized based on these topics.
Results: The search generated 5632 articles. After screening titles and abstracts, 164 articles were retrieved and read: 56
articles met the final inclusion criteria; 23 were reviews (narrative or systematic); 16 were original articles containing
epidemiological data; and six contained treatment specifications for patients with rhabdomyolysis.
Conclusion: Most studies defined rhabdomyolysis based on creatine kinase values five times above the upper limit of
normal. Etiologies differ among the adult and pediatric populations and no randomized controlled trials have been
done to compare intravenous fluid therapy alone versus intravenous fluid therapy with bicarbonate and/or mannitol.
Keywords: Rhabdomyolysis, Acute kidney injury, Myoglobinuria, Myopathy
Background
Rhabdomyolysis is a clinical entity characterized by the
destruction of skeletal muscle with resultant release of
intracellular enzymatic content into the bloodstream
that leads to systemic complications [1, 2]. The classic
presentation of this condition is muscle pain, weakness,
dark tea-colored urine (pigmenturia), and a marked ele-
vation of serum creatine kinase (CK) five to ten times
above the upper limit of normal serum levels [3]. The
global incidence of rhabdomyolysis remains unknown
but several population risk groups have been identified
(i.e., morbid obese patients, chronic users of lipid-
lowering drugs, post-operative patients) [4–6].
The term “crush syndrome” is usually used to describe
muscle destruction after direct trauma, injury, or com-
pression [7]. It was first described in 1941, when
Bywaters and coworkers established a relationship be-
tween muscle necrosis and a brown pigment found by
autopsy in the renal tubules of patients buried for sev-
eral hours during a bomb attack in London [8]. Man-
made and natural disasters comprise the majority of
cases of crush syndrome-associated rhabdomyolysis with
development of life-threatening complications to this
day [7].
Acute kidney injury (AKI) is the most common sys-
temic complication of rhabdomyolysis. It occurs at an
incidence ranging between 10 and 55 % and is associated
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with a poor outcome, particularly in the presence of
multiple organ failure [9]. Therefore, preservation of
renal function with intravenous (IV) fluid therapy re-
mains the cornerstone of rhabdomyolysis treatment [10].
The importance of rapid initiation of IV fluid therapy in
the management of patients with rhabdomyolysis was
first documented by Ron and coworkers in 1984 [11];
among the seven patients treated with fluids on-site dur-
ing a disaster, none developed AKI. This finding received
further support in additional studies suggesting that
prompt IV fluid administration is associated with better
patient outcome [12–14].
No guidelines for the management of rhabdomyolysis
are available; nor have any randomized controlled trials
of treatment been conducted. Recommendations for
fluid therapy in rhabdomyolysis have yet to be estab-
lished in terms of fluid type, volume, and time of initi-
ation. Management of rhabdomyolysis is currently based
on observations from retrospective studies, case reports,
and case series which describe diverse and often parallel
medical treatments for this syndrome and for its most
common complication, AKI [10, 15].
Most of the current knowledge is based on historical
data and has been unchanged for more than a decade.
Therefore, the aim of this review is to summarize the lit-
erature published in the past 10 years (2006–2015) to
update the definition, etiological classification, patho-
physiology, diagnosis, epidemiology (e.g., risk factors,
population and subgroup incidence, common etiologies,




Two authors (LOC and ML) independently searched
the medical literature published in three databases
(MEDLINE, SCOPUS, and ScienceDirect) for articles
that included in their title or abstract the keywords
“rhabdomyolysis” or “crush syndrome”. The search
covered all articles from January 2006 to December
2015; we selected this period to increase knowledge
and provide an updated review based on the existing
literature from the past 10 years. All types of articles,
including reviews (narrative and systematic), random-
ized controlled trials (RCTs), case-control cohorts,
case series, and case reports were screened for rele-
vant content. Abstracts from the selected articles were
read and, if considered eligible for further review, the
complete article was obtained.
Search approach
Data collection and extraction were divided into two
steps. The first step was intended to identify the articles
with data relevant for extraction regarding definition,
pathophysiology, and diagnosis of rhabdomyolysis. In
order to qualify for inclusion the article was to contain
any information regarding the following: definition, etio-
logical classification, pathophysiology, or diagnosis of
rhabdomyolysis.
The second step was intended to identify original
research articles that included data regarding the epi-
demiology (e.g., risk factors, population and subgroup
incidence, common etiologies, and morbidity and mor-
tality) or treatment of rhabdomyolysis. To this end we
searched MEDLINE using the keywords noted above
(“rhabdomyolysis” or “crush syndrome”) and added a fil-
ter selecting “humans” in the “Species” field. We selected
for inclusion only original research articles which con-
tained specifics of human epidemiological data or treat-
ment. Excluded were articles referring to treatment of
rhabdomyolysis-induced AKI only, case reports, and
laboratory investigations of rhabdomyolysis. Repeated
publications and articles not in English or Spanish were
also excluded. Figure 1 shows a flowchart for study
selection.
Data collection
Controversies regarding article eligibility for data extrac-
tion were resolved by a third author (JV). The references
from the selected articles that had been retrieved were
also screened for additional possible references. After
determining the relevance of each paper, the articles
were divided into several files according to their topic
relevance (definition, etiology and epidemiology, patho-
physiology, diagnosis, and treatment). There was no
limit to the number of files an article could appear in.
Finally, the data from each topic file were summarized.
No additional statistical analysis was performed.
Results
The two searches generated 5632 articles overall. After
screening the titles of all these articles, only 286 poten-
tially relevant articles remained. The abstracts of these
articles were screened and only 164 articles contained
information relevant to the topic files. These 164
complete articles were retrieved and read. Only 56 arti-
cles met final inclusion criteria; single case reports and
articles published in a language different from English or
Spanish were excluded. This systematic review includes
reference to 23 reviews (narrative or systematic) which
include information regarding definition, etiological clas-
sification, pathophysiology, and diagnosis of rhabdo-
myolysis. It also includes reference to 16 original articles
which met inclusion criteria for epidemiological data
extraction and six original articles which met inclusion
criteria for treatment. Table 1 lists the original articles
that included data on risk factors, etiology, and epidemi-
ology of rhabdomyolysis. Table 2 lists the original
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The clinical studies were very heterogeneous with regard
to the definition of rhabdomyolysis; although most au-
thors diagnosed rhabdomyolysis based on CK levels five
times the upper limit of normal levels (>1000 U/L),
others used alternative criteria for diagnosis (Table 1)
[16–31]. In the clinical setting, symptoms were not usu-
ally taken into consideration when defining rhabdomyol-
sysis; however, the most commonly included ones were
muscle pain and muscle weakness while the presence of
dark urine was not used to define this entity in most
studies [16, 18, 21]. When rhabdomyolysis is associ-
ated with the use of lipid-lowering drugs (statins,
fibrates, or a combination of both), the CK level cut-
off is considered ten times the upper limit of normal
[30, 32, 33]. The definition of severity of rhabdo-
myolysis varied among studies, some defining “severe
rhabdomyolysis” based on different CK cutoff values
(>5000 U/L up to >15,000 U/L) [26, 34].
Epidemiology and etiology
Many cases of rhabdomyolysis are not detected and
the incidence of this clinical entity has been reported
only in subgroups of populations at risk [5, 6, 9, 35].
Rhabdomyolysis is more frequent among males, African-
Americans, patients <10 and >60 years old, and in people
with a body mass index exceeding 40 kg/m2 [5, 6].
The causes of rhabdomyolysis have been classified
differently by several authors. Zimmerman and Shen
[36] used a classification based on their mechanism
of injury (hypoxic, physical, chemical, and biologic).
Other authors described alternative classifications such as
physical/non-physical, exertional/non-exertional, and ac-
quired/inherited [2, 37–39]. Table 3 distinguishes rhabdo-
myolysis according to acquired and inherited causes and
includes some examples of the most common etiologies
reported in the medical literature. Causes of rhabdomyoly-
sis are also different depending on the age; trauma, drugs,
and infections are the most commonly reported in adults
[19, 24, 26] while trauma, viral infections, drugs, and exer-
cise etiologies prevail in children [16, 27–29].
Muscle toxicity due to several drugs may arise either by
a direct mechanism or through drug interactions [23, 40].
Fig. 1 Flowchart for study selection
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Table 1 Studies with epidemiological data
Article Type of
study
Type of patients RM definition Etiologies Risk factors Patients with RM Comments
Mannix et al. 2006 [16] RS Pediatric patients in
the ED
CK level >1000 IU/L Viral myositis, trauma,
connective tissue disease
NA RM = 191 Most common reported
symptoms were muscle
pain and fever.
AKI developed in only nine
patients
Lagandre et al. 2006 [17] POS 49 bariatric post-operative
patients
CK level >1000 IU/L NA Surgical time >4 h,
diabetes, BMI >40 kg/m2
RM = 13 Type of surgeries performed
were gastric banding or
bypass
De Oliveira et al. 2009 [18] POS 22 bariatric post-operative
patients
An increase >5× the upper
limit of the normal CK level
NA Prolonged surgical
duration
RM = 17 Clinical neuromuscular
symptoms occurred in 45 %
of patients




NA RM = 106 The authors suggest that
RM should be defined using
CK levels above 10–25 times
the upper limit of normal.
AKI developed in 52 patients




NA BMI >56 kg/m2 RM = 7 Factors such as sex, age, and
length of surgery were not
good predictors of RM
Alpers et al. 2010 [21] RS Patients in military training Muscle pain, weakness,
or swelling over <7 days
with a CK >5× the upper
limit of normal
Exertional RM NA RM = 177 Authors comment that
exertional RM is associated
with lower incidence of AKI
Bache et al. 2011 [22] RS 76 burn patients in the
ICU
“Late-onset” RM: CK
>1000 U/L, 1 week or






CK in all patients with the
risk factors described in burn
patients to initiate prompt
treatment
Oshima 2011 [23] RS Cases of drug-related RM NA Drug use <10 year olds, weight
less than 50 kg
RM = 8610 Lipid lowering drugs were
most frequently reported as
the associated drugs
Herraez Garcia et al. 2012 [24] RS Adult hospitalized patients CK level of 5× upper limit
(975 UI/L)
Trauma, sepsis, immobility Elder patients and
male sex
RM = 449 No relationship was found
between CK levels and AKI
development or mortality





RM = 342 The authors found a
correlation between CK











Table 1 Studies with epidemiological data (Continued)
Rodriguez et al. 2013 [26] RS Acute-care hospital
patients
Severe RM: >5000 IU/L Immobilization, illicit drug
abuse, infections, trauma







Chen et al. 2013 [27] RS Pediatric patients in
the ED
CK levels >1000 IU/ Infection, trauma, exercise NA RM = 37 Common symptoms were
muscle pain and weakness.
Dark urine reported in 5.4 %
of patients
Talving et al. 2013 [28] RS Pediatric trauma patients NA Trauma NA RM = 521 AKI occurred in 70 patients.
The authors concluded that
a CK level ≥3000 was an
independent risk factor for
developing AKI
Grunau et al. 2014 [29] RS Patients in the ED CK levels >1000 U/L Illicit drug use, infections,
trauma
NA RM = 400 AKI developed in 151
patients; 18 patients
required hemodialysis
van Staa et al. 2014 [30] RS 641,703 statin users CK levels 10× the upper
limit of normal
Statin drug use Drug–drug interaction Reported with
RM = 59
CK >10× = 182
The incidence of RM in this
cohort of statin users was
very low
Pariser et al. 2015 [31] RS 1,016,074 patients with a
major urologic surgery
NA NA Diabetes, chronic kidney
disease, obesity, bleeding,
age and male sex
RM = 870 Surgeries associated with
RM were nephrectomy
(radical or partial) and
radical cystectomy











A retrospective study of 8610 cases of drug-associated
rhabdomyolysis reported to the US Food and Drug
Administration (FDA) from 2004 to 2009 found that sim-
vastatin, atorvastatin, and rosuvastatin were most fre-
quently suspected and accounted for 3945 cases (45 %)
[23]. Statin drugs all have the potential to cause muscle
damage in a dose-dependent manner, although they
vary in several characteristics. Simvastatin, atorva-
statin, and lovastatin are metabolized by CYP3A4 (the
most common cytochrome P450 isozyme), which ne-
cessarily leads to competition with other drugs for
metabolism, increasing statin blood levels and predis-
posing to toxicity [41]. Rosuvastatin and fluvastatin
are metabolized by the CYP2A9 isozyme and there-
fore carry less risk of drug interaction [41]. Some de-
gree of muscle toxicity is experienced by 0.08–10 %
of patients being treated with statins alone or in com-
bination with other lipid-lowering drugs [6, 32, 33].
However, less than 1 % have significant elevation of
serum CK levels [30].
The number of rhabdomyolysis cases associated with
surgery seems to have been increasing over recent years
[5, 17]. Several related risk factors include extended
length of surgery and comorbidities such as obesity
and diabetes [17, 25, 31]. As the length of surgery in-
creases, so does the time spent in immobility, raising the
likelihood of secondary tissue compression and ischemia.
Drugs used for anesthesia (propofol, barbiturates, benzo-
diazepines, and opiates) have also been associated with
rhabdomyolysis [35].
Pathophysiology
Regardless of the cause of rhabdomyolysis, the patho-
physiology of muscle destruction follows a common
pathway. The muscle cell is affected either by direct cell
membrane destruction or by energy depletion [9]. Free
ionized calcium enters the intracellular space and acti-
vates proteases and apoptosis pathways [2]. Production
of reactive oxygen species (ROS) leads to mitochondrial
dysfunction and ultimately to cell death [2, 37].
Muscle cell calcium homeostasis is normally maintained
by transmembrane proteins (i.e., channels, pumps), most
of which are energy-dependent [42]. When energy (in the
form of ATP) depletes, ATPase pump dysfunction is
accompanied by an increase in intracellular Na+ concen-
tration, activating the 2Na+/Ca2+ exchanger in order to
correct ionic abnormalities [38]. The parallel secondary
increase in intracellular calcium activates proteases such
as the phospholipase A2 (PLA2) enzyme, which destroys
both cellular and mitochondrial membranes [2, 37].
Figure 2 illustrates the cascade of events leading to muscle
cell lysis.
Table 2 Studies included with treatment details
Article Type of
study
Population IV fluid Bicarbonate/mannitol Rate of AKI and need for RRT
Altintepe et al.
2007 [55]
CS N = 9 Fluid type used 5 % dextrose and
0.45 NS.
4–8 L of IV fluid daily
40 mEq NaHCO3 and 50 mL of
20 % mannitol mixed with 1 L
of IV fluid (0.45 % NaCl and 5 %
dextrose)
They targeted a urine pH above
or equal 6.5




Cho et al. 2007 [56] PS N = 28 Fluid therapy consisted of lactated
Ringer’s solution (13 patients)
versus NS (15 patients) (the
authors concluded that LR was
more useful than NS)
IV fluid rate 400 mL/h
Bicarbonate was used to achieve
urine pH ≥6.5 in the patients
with NS IV fluid
No patient developed AKI
Talaie et al. 2008 [51] RS N = 156 Fluid therapy given 1–8 L in the
first 24 h (mean IV fluid 3.2 L/24 h)
Bicarbonate was given to
115 patients




RS N = 28 36 % of the patients received
saline infusion (20 mL/kg) in the
first 24 h
79 % of patients received
sodium bicarbonate IV fluid
11 patients (39.2) developed
AKI
7 patients with CK levels
>5000 U/L required RRT
Sanadgol et al.
2009 [58]
CS N = 31 0.45 % NS 15 mEqL NaHC03 mixed with
IV fluid
Alkaline IV solution 3–5× more
than maintenance rate was used
8 patients (25.8 %) developed
AKI
Iraj et al. 2011 [34] PS N = 638 Authors recommend >6 L/day in
severe RM and ≥3 L/day IV fluid
in moderate RM to decrease the
incidence of AKI
NA 134 patients (21 %) developed
AKI
110 patients required RRT
Abbreviations: AKI acute kidney injury, CS case series, IV intravenous, NA not available, NS normal saline, PS prospective study, RM rhabdomyolysis, RRT renal
replacement therapy, RS retrospective study
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Following muscle cell necrosis, release of cytotoxic
intracellular components causes capillary injury and
leads to third-spacing of fluids [3]. Edema, ischemia, and
cell necrosis cause additional metabolic acidosis and
electrolyte abnormalities, perpetuating the vicious cycle
of cell death [36].
Mechanisms of AKI
Rhabdomyolysis-associated AKI may be induced through
several mechanisms, including hypovolemia, myoglobi-
nuria, and metabolic acidosis (Fig. 3) [9, 43].
During muscle destruction, intracellular fluid is first
leaked then sequestered in extracellular spaces. This de-
pletes the intravascular volume and activates the renin–
angiotensin–aldosterone system, decreasing renal blood
flow [2, 9]. Release of myoglobin, the oxygen-carrier pro-
tein of the muscle, into the systemic circulation exerts a
cytotoxic effect on the nephron both directly and
through its compounds. The free iron released after
myoglobin breakdown in the kidney reacts with hydro-
gen peroxide compounds (Fenton reaction), generating
ROS which damage renal tubular integrity [42]. A sec-
ond mechanism of kidney injury is lipid peroxidation:
lipid membrane components in the kidney react with
the ferryl form of myoglobin, a process called redox cyc-
ling [42]. The presence of metabolic acidosis potentiates
myoglobin nephrotoxicity by promoting cast formation
and tubular obstruction, particularly in the distal convo-
luted tubules [3].
Besides myoglobin, uric acid is also released from nec-
rotic muscle. Uric acid forms deposits of crystals in an
acidic environment, further contributing to tubular ob-
struction [44]. A similar pathophysiology is observed in
tumor-lysis syndrome: cell damage and substance release
with subsequent AKI [45].
Diagnosis
The classic symptoms associated with rhabdomyolysis
include severe muscle pain, weakness, and the presence
of dark tea-colored urine, which are highly suggestive of
the diagnosis [3]. Patients may also present with oliguria
or even anuria [27]. Systemic circulation of intracellular
muscle components can yield additional non-specific
symptoms. Cardiovascular symptoms may stem from the
associated electrolyte abnormalities (i.e., potassium,
calcium, phosphate) and may range from cardiac dys-
rhythmias to cardiac arrest [10]. Patients may be
hyperventilating due to pain if they are awake and ag-
itated or hypoventilating if rhabdomyolysis was drug-
induced or due to trauma [19, 28]. Drug-induced syn-
dromes associated with rhabdomyolysis (neuroleptic
malignant syndrome and malignant hyperthermia) are
characterized by muscle rigidity, hyperthermia, and
metabolic acidosis [10, 35].
Laboratory work-up
Serum CK levels gradually increase during the first
12 h of rhabdomyolysis, peak within 3–5 days, and
return to baseline during the following 6–10 days
[39]. Clinicians often use serum CK levels exceeding
five times the upper limit of normal for diagnosing
rhabdomyolysis [18, 21, 24].
Urinalysis can detect the presence of myoglobin when it
exceeds 0.3 mg/L in serum [2]. The heme molecule reacts
in a urine dipstick but this method cannot distinguish be-
tween a positive result due to the presence of hemoglobin
or myoglobin [37]. Myoglobinuria can be considered when
a patient has a reactive heme test positive for blood but
the microscopic exam reveals only few red blood cells in
the urine [38]. The urine pH tends to be acidic and it
often contains detectable levels of protein [2, 3].
Serum CK levels have traditionally been considered
the best predictor of AKI [25, 46]. However, Baeza-
Trinidad and coworkers [47] recently conducted a retro-
spective study of 522 patients with rhabdomyolysis in
which both initial CK and creatinine levels were re-
corded. In this study, the initial CK level was not a pre-
dictor of AKI [47]. Serum myoglobin has also been used
as a predictor of AKI; Premru and coworkers [48] found
that >15 mg/L of myoglobin in the blood was highly
Table 3 Rhabdomyolysis etiology classification [2, 25–27, 44]
Type Cause Examples
Acquired Trauma “Crush syndrome”




Illicit drugs Cocaine, heroin, LSD
Alcohol Acute or chronic consumption
Drugs Dose-dependent, multiple
interactions
Infections Bacterial, viral, parasitic




Toxins Spider bites, wasp stings,
snake venom
Inherited Metabolic myopathies Glycogen storage, fatty acid,
mitochondrial disorders
Structural myopathies Dystrophinopathy, dysferlinopathy
Channel related gene
mutations
RYR1 gene mutation, SCN4A gene
mutation
Others Lipin-1 gene mutation, sickle-cell
disease, “benign exertional
rhabdomyolysis”
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associated with development of AKI in a cohort of 484
patients. However, data regarding the use of myoglobin
as an early marker of rhabdomyolysis-associated AKI
remains inconclusive since many values of myoglobin
overlap [49].
The Risk, Injury, Failure, Loss, and End-stage kid-
ney disease (RIFLE) criteria are used in most studies
nowadays to define AKI [50]. However, different cri-
teria have been used to establish the diagnosis of AKI
after rhabdomyolysis in clinical studies [34, 51]. Talaie
Fig. 3 Acute kidney injury in rhabdomyolysis. Enzymes*: creatine kinase, aldolase, lactate dehydrogenase. After muscle destruction, myoglobin and
enzymes released into the circulation damage capillaries, leading to leakage and edema. Hypovolemia and the decrease in renal bood flow is
associated with acute kidney injury. Myoglobin cytotoxicity affects the kidney by lipid peroxidation and production of reactive oxygen species.
Tubular obstruction by myoglobin is also associated with AKI
Fig. 2 Injury mechanisms of rhabdomyolysis. (1) Energy (ATP) depletion inhibits Na+/K+ ATPase function, thus increasing intracellular sodium.
(2) The 2Na+/Ca2+ exchanger increases intracellular calcium. (3) Ca2+ ATPase is not able to pump out intracellular calcium due to energy depletion.
(4) Intracellular calcium activates proteases such as phospholipase 2 (PLA2), which destroy structural components of the cell membrane, allowing the
entrance of more calcium. (5) Calcium overload disrupts mitochondrial integrity and induces apoptosis leading to muscle cell necrosis
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and coworkers [51] diagnosed rhabdomyolysis-induced
AKI in patients with a serum creatinine level eleva-
tion of more than 30 % in the first days of admission.
In another study, Iraj and coworkers [34] established
a diagnosis based on two repeated values of creatinine
≥1.6 mg/dL.
The presence of AKI may be accompanied by exces-
sive potassium levels, correlating with the degree of
muscle destruction. These levels should be followed
closely due to the risk of cardiac dysrhythmias [36]. Ser-
ial electrocardiography studies should also be performed
to detect abnormalities secondary to electrolyte distur-
bances [10].
Prolongation of the prothrombin time, thrombo-
cytopenia, and high levels of fibrinogen degradation
products may also be detected during rhabdomyolysis
[10, 52]. In this setting, serial blood tests are indicated to
detect disseminated intravascular coagulopathy as early
as possible. Arterial blood gases typically demonstrate
metabolic acidosis with an elevated anion gap, reflecting
the increase in organic acid levels in the serum due to
muscle necrosis [2, 26].
Initial CK and myoglobin levels are inconsistent in
predicting mortality or AKI in rhabdomyolysis [49, 53].
McMahon and coworkers [53] have recently validated an
instrument for predicting mortality and AKI. This score
includes eight variables: age, gender, etiology, and initial
levels of creatinine, calcium, phosphate, and serum
bicarbonate.
Treatment
Treatment of the underlying source of muscle injury,
once identified, is the first component of successful
management. This may include cessation of a potentially
harmful drug, control of patient temperature, treatment
of underlying infection, and more [7, 51].
IV fluid therapy
Fluid replacement is the keystone of rhabdomyolysis
treatment. Capillary damage and fluid leakage lead to a
“functional” dehydration that requires rapid correction
[54]. Early, aggressive fluid therapy increases renal blood
flow, thereby increasing secretion of nephrotoxic com-
pounds that may cause AKI [9].
Table 2 shows studies in which IV fluid therapy was
described for patients diagnosed with rhabdomyolysis
[34, 51, 55–58]. The type of IV fluid varied from the
combination of 5 % dextrose and 0.45 normal saline
(NS), lactated Ringer’s solution, and NS solution with or
without bicarbonate [51, 55, 56]. Fluid administration
was reported either as an hourly or daily rate. Cho and
coworkers [56] prospectively studied 28 patients treated
with either NS or lactated Ringer’s solution with an
IV fluid rate of 400 mL/h and none of the patients
developed AKI. Other studies used from 4 to 8 L of
IV fluid daily [34, 51, 55].
In 2013, Scharman and coworkers [54] conducted a
systematic review of therapies for prevention of
rhabdomyolysis-associated AKI; overall, 27 studies were
included. The authors concluded that IV fluid therapy
should ideally be initiated within 6 h of muscle injury,
targeting a urine output of 300 mL/h. No specific rec-
ommendations were provided regarding the type of fluid
because of the variety of intravenous fluids used in the
different studies [54].
In non-traumatic rhabdomyolysis, the use of lactated
Ringer’s solution was compared with NS in a cohort of
28 patients divided into 13 patients treated with Ringer’s
solution and 15 patients treated with NS. No significant
difference was found either in the rate of reduction of
CK levels or in the prevalence of AKI in both groups
[56]. Despite the poor literature comparing different
fluids, Sever and coworkers suggested in a supplement
published in Nephrology, Dialysis, Transplantation enti-
tled “Recommendation for the management of crush vic-
tims in mass disasters” that isotonic saline should be the
initial choice for volume correction in rhabdomyolysis
secondary to crush injury [15]. These authors also sug-
gested that initial fluid infusion rates should be 1 L/h for
2 h after injury and 500 mL/h after 120 minutes [15].
However, these recommendations were not based on
randomized clinical trials. Patients receiving fluid re-
placement therapy should be monitored closely to pre-
vent complications such as fluid overload and metabolic
acidosis [59].
Treatment of electrolyte abnormalities
Reinstatement of the biochemical equilibrium during
rhabdomyolysis should be undertaken with care in order
to avoid adverse effects of treatment. Hyperkalemia is
the only electrolyte abnormality that requires rapid
correction in order to reduce the risk of cardiac dys-
rhythmias [43, 60]. Administration of calcium chloride/
gluconate for hypocalcemia should be avoided since cal-
cium supplementation may increase muscle injury [10].
Correction of hyperphosphatemia requires careful moni-
toring of both phosphorus and calcium levels since
increased levels of phosphorus may promote calcium
deposition in necrotic muscle tissue [10].
Bicarbonate for prevention of AKI
The use of bicarbonate for prevention of AKI is based
on the concept that an acidic environment promotes
myoglobin toxicity; hence, an alkali urine environment
may reduce redox-cycling, lipid peroxidation, and myoglo-
bin cast formation [9]. It is thus plausible that increasing
urine pH above 6.5 with intravenous sodium bicar-
bonate could prevent AKI [55]. Besides AKI prevention,
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several authors have suggested that sodium bicarbon-
ate should be used to correct metabolic acidosis [38].
However, administration of sodium bicarbonate may
also produce paradoxical intracellular acidosis and
volume overload, particularly in patients with respira-
tory or circulatory failure, when the bicarbonate buff-
ering system shifts to increase circulating carbon dioxide
(HCO3 +H
+→H2CO3→H20 + CO2) [61].
Table 2 includes some of the “bicarbonate cocktails”
added to IV fluid therapy in some studies. However,
none of the studies have actually compared this therapy
with intravenous fluid therapy alone [51, 58].
Mannitol
There is no consensus regarding the use of mannitol
since its side effects include volume depletion and po-
tentially worsening pre-renal azotemia [9]. However, the
theoretical benefits of mannitol administration include
improved diuresis, increased renal perfusion, excretion
of myoglobin, and a direct antioxidant effect on renal
parenchyma [62]. Authors that recommend using
mannitol suggest it should only be administered if
fluid therapy alone does not lead to urine output ex-
ceeding 300 mL/h [15]. Mannitol should be avoided
in anuric patients; it is therefore recommended to as-
sess the urinary response starting only with IV fluids
prior to deciding whether to proceed with mannitol
administration [15].
Continuous renal replacement therapy
Continuous renal replacement therapy (CRRT) clears
myoglobin from the bloodstream, thereby potentially de-
creasing the amount of renal damage [63, 64]. Zeng and
coworkers [60] systematically reviewed the potential
benefits of CRRT in patients with rhabdomyolysis and
AKI. The authors found only three studies for inclusion
in their review (n = 101 patients). They concluded that,
despite the improvement in myoglobin, creatinine, and
electrolyte levels in patients treated with CRRT, mortal-
ity rates remained unchanged [60]. CRRT should there-
fore only be considered when life-threatening electrolyte
abnormalities emerge as complications of AKI that are
non-responsive to initial therapy [43].
Conclusions
Rhabdomyolysis remains a major clinical challenge.
Non-specific symptoms, multiple etiologies, and systemic
complications obscure the diagnosis and complicate the
treatment of this condition. The pathophysiology of
myoglobin-induced injury to the renal parenchyma has
been elucidated and aggressive fluid therapy remains the
keystone of therapy. However, RCTs are sorely lacking
regarding the use of both fluids and adjuvant pharmaco-
logical therapies (mannitol and bicarbonate) for AKI
prevention. CRRT improves myoglobin clearance but does
not change mortality. Several important aspects of
rhabdomyolysis should be addressed in the future: a
homogenous definition should be created for this syn-
drome, data from past cases should be pooled to derive
and validate the best marker for predicting development
of AKI, and multicenter RCTs that compare standardized
intravenous fluid therapy alone with fluids with sodium
bicarbonate and/or mannitol should be planned.
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